• MainImage1
  • MainImage2
  • MainImage3
1 2 3

Key Opinion Leaders

  • ChrisMcguigen1

New Generation Anti-Cancer Agents

NUC1031 molecular structue

Our ProTide technology has the potential to create a paradigm shift in cancer treatment. The unique feature of ProTides is their ability to overcome the key resistance mechanisms associated with the current standards of care. Acelarin, our first agent in the clinic, has achieved exceptional levels of disease control for patients with advanced, rapidly progressing solid tumours.